Clinical Trial Update: DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Poly ICLC, Decitabine, and Nivolumab in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating the safety of a multi-agent regimen (CDX-1401, Poly ICLC, Decitabine, and Nivolumab) in patients with myelodysplastic syndromes and acu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Anemia
• High-risk Myelodysplastic Syndrome
• Myelodysplastic Syndrome
• Myelomonocytic Leukemia

Drugs mentioned

• CDX-1401
• Dacogen (decitabine)
• Hiltonol (poly-ICLC) (poly-ICLC)
• nivolumab (nivolumab)

Snippet

Sponsor: Roswell Park Cancer Institute | Conditions: Acute Myeloid Leukemia, Blasts 30 Percent or Less of Bone Marrow Nucleated Cells | Phase 1 | Status: COMPLETED | Results posted: 2026-02-27